home

What are your concerns?

close
Inaccurate
Hard to understand
Other

Share


Or copy link

New

Paxlovid: Pfizer's Antiviral Pill Found To Be 89% Effective Against Severe COVID-19

Paxlovid: Pfizer's Antiviral Pill Found To Be 89% Effective Against Severe COVID-19

Pfizer doesn’t just offer a COVID-19 vaccine with high efficacy, they now also have Paxlovid, an antiviral that reduces COVID-related hospitalization and death by up to 89%. Here’s what you need to know about this medicine.

Paxlovid, An Overview

Before we outline Paxlovid’s mechanism of action and how people should take it, let’s first emphasize that this experimental medicine is not meant to be a substitute for vaccination. While Pfizer’s antiviral maybe 89% effective in high-risk cases, vaccination prevents hospitalization and death by 100%.

With that said, let’s now discuss what could be the most frequently asked questions about Paxlovid:

1. How Does It Work?

Paxlovid is a protease inhibitor, which means it blocks protease, an enzyme that SARS-CoV-2 needs to reproduce.

Hence, when a person takes Paxlovid, their viral load might not increase too much. This is important because there seems to be an association between higher viral load and more serious symptoms.

2. Do You Take Pfizer’s Antiviral on Its Own?

Reports say Pfizer’s antiviral is taken alongside a small dose of ritonavir, an old antiviral that makes Paxlovid stay longer in the body. Please note that ritonavir may cause gastrointestinal side effects and might even interfere with other medicines.

3. How Do You Take Paxlovid?

In the clinical trials, patients took three pills of Paxlovid twice a day (every 12 hours) for 5 days.

Paxlovid’s Effectiveness According to Clinical Trials

In its clinical trial involving more than 1,200 high-risk patients with COVID-19, Pfizer researchers divided the participants into two: one receiving Paxlovid, the other receiving placebo.

Results show that 7% of participants who received placebo got hospitalized while only 0.8% of those who received Paxlovid required hospital confinement. Seven people died in the placebo group; none in the treatment group. Note that these participants received the treatment within 3 days of having symptoms.

Those who received treatment within 5 days had slightly different, but still promising results: they discovered that 6.7% of patients in the placebo group were hospitalized compared to only 1% of the participants who received Paxlovid1. Also, none of the participants died in the treatment group, but 10 died in placebo2.

How Does Paxlovid Compare to Molnupiravir?

Besides Paxlovid, Merck, the maker of the controversial Ivermectin, also had an experimental antiviral called Molnupiravir. But how do these two drugs compare with each other?

First, initial data show that Pfizer’s antiviral is more effective. Where Paxlovid is up to 89% effective in high-risk patients, Molnupiravir is only about 50% effective.

Another key difference is the dosage. While Paxlovid and Molnupiravir should both be taken for 5 days, the first only needs 30 pills while Merck’s antiviral requires 40 pills: 4 pills taken twice a day3.

Also, their mechanisms of action are different. Where Pfizer’s pill blocks the enzyme that SARS-CoV-2 needs to reproduce, Merck’s works by triggering genetic errors, which also inhibit replication.

Just like what happened with Molnupiravir, the authorities also ceased the clinical studies with Paxlovid because the initial results were already so promising.

Finally, let’s discuss which is more expensive. Recent reports indicated that the US has a $1.2 billion contract with Merck for 1.7 million courses of Molnupiravir. That means each course costs about $700. Pfizer has not made any public announcement about the potential cost of their antiviral.

Why These Medicines Are So Important

While Paxlovid and Molnupiravir are not substitutes for vaccination, they are still considered game-changers, especially for people who cannot have the vaccine or are hesitant to take it.

If approved, Paxlovid (along with Merck’s pill, which is already approved in the United Kingdom5) will help end the pandemic.

Key Takeaways

Pfizer’s experimental antiviral, Paxlovid, appears to be 89% effective against high-risk COVID-19 infections that result in hospitalization or death. If approved, it will be a welcome addition to the world’s arsenal in ending the pandemic.

Learn more about Health News here.

Hello Health Group does not provide medical advice, diagnosis or treatment.

Sources

1. Covid: Pfizer says antiviral pill 89% effective in high-risk cases, https://www.bbc.com/news/health-59178291, Accessed November 9, 2021

2. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports, https://www.bmj.com/content/375/bmj.n2713, Accessed November 9, 2021

3. How Merck’s antiviral pill could change the game for COVID-19, https://www.nationalgeographic.com/science/article/how-mercks-antiviral-pill-could-change-the-game-for-covid-19, Accessed November 9, 2021

4. Explainer: How does Merck’s COVID-19 pill compare to Pfizer’s?, https://www.reuters.com/business/healthcare-pharmaceuticals/how-does-mercks-covid-19-pill-compare-pfizers-2021-11-05/, Accessed November 9, 2021

5. Molnupiravir: First pill to treat Covid gets approval in UK, https://www.bbc.com/news/health-59163899, Accessed November 9, 2021

6. PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY, https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate, Accessed November 9, 2021

Picture of the authorbadge
Written by Lorraine Bunag, R.N. Updated 2 weeks ago
Fact Checked by Kristel Lagorza